Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7352 participants.
Also called NCT02545049
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,352 participants
- Sponsor
- Registry
-
NCT02545049 -
2015-000950-39
-
- Other papers using this trial's data
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Ireland, Israel, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT02545049. Randomized; quadruple masking; primary purpose treatment. Start 2015-09-17 (actual); primary completion 2021-02-02 (actual). Results posted on 2022-04-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
- Acronym
- FIGARO-DKD
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- Finerenone (BAY94-8862)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct02545049- Content hash
0ebcba67f32e7a9f972508935d83247de655e4b01d41d5b8fc07ba1aa549c018